Isabelle Rose Leo

Keywords TCR CAR peptide T cell immunotherapy Get full text access Log in, subscribe or purchase for full access. References 1. Uslu, U. ∙ June, C.H. Beyond the blood: expanding CAR T cell therapy to solid tumors Nat. Biotechnol. 2025; 43:506-515 2. Brudno, J.N. ∙ Kochenderfer, J.N. Current understanding and management of CAR T cell-associated toxicities Nat. Rev. Clin. Oncol. 2024; 21:501-521 3. Madrenas, J. ...

Abstract Proteome-wide profiling has revealed that targeted drugs can have complex protein interaction landscapes. However, it’s a challenge to profile drug targets while systematically accounting for the dynamic protein variations that produce populations of multiple proteoforms. We address this problem by combining thermal proteome profiling (TPP) with functional proteoform group detection to refine the target landscape of ibrutinib.

Abstract Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Although standard-of-care chemotherapeutics are sufficient for most ALL cases, there are subsets of patients with poor response who relapse in disease. The biology underlying differences between subtypes and their response to therapy has only partially been explained by genetic and transcriptomic profiling.